|
ELANE expression based on
|
*
Please note that the TPM values for gene considered is extremely low (TPM < 1).
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.999500E-03 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.778800E-01 |
| Normal-vs-Stage2 |
9.593000E-01 |
| Normal-vs-Stage3 |
1.534130E-02 |
| Normal-vs-Stage4 |
1.738260E-02 |
| Stage1-vs-Stage2 |
6.098000E-01 |
| Stage1-vs-Stage3 |
1.627180E-01 |
| Stage1-vs-Stage4 |
3.336200E-02 |
| Stage2-vs-Stage3 |
1.620960E-01 |
| Stage2-vs-Stage4 |
2.990300E-02 |
| Stage3-vs-Stage4 |
1.074820E-01 |
|
|
*
Please note that the TPM values for gene considered is extremely low (TPM < 1).
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.063000E-03 |
| Normal-vs-AfricanAmerican |
3.173000E-01 |
| Normal-vs-Asian |
3.006800E-01 |
| Caucasian-vs-AfricanAmerican |
6.934200E-01 |
| Caucasian-vs-Asian |
7.743800E-01 |
| AfricanAmerican-vs-Asian |
6.181000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.218300E-03 |
| Normal-vs-Female |
1.097980E-01 |
| Male-vs-Female |
6.873800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.011600E-01 |
| Normal-vs-Age(41-60Yrs) |
3.213700E-02 |
| Normal-vs-Age(61-80Yrs) |
1.299040E-01 |
| Normal-vs-Age(81-100Yrs) |
3.062800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.430400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.467800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.319000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.698600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.623400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.637600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.130400E-01 |
| Classical-VS-Follicular |
3.662200E-03 |
| Classical-VS-Other |
7.561800E-01 |
| Classical-VS-Normal |
6.236700E-03 |
| Tall-VS-Follicular |
5.916900E-03 |
| Tall-VS-Other |
6.333800E-01 |
| Tall-VS-Normal |
1.218490E-02 |
| Follicular-VS-Other |
3.223000E-01 |
| Follicular-VS-Normal |
2.643600E-01 |
| Other-VS-Normal |
4.152000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.286000E-01 |
| Normal-vs-N1 |
1.143530E-02 |
| N0-vs-N1 |
2.157600E-02 |
|
|
